Your browser doesn't support javascript.
loading
Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study.
Brandsen, Rajani P; Diederen, Roselie M H; Bakhlakh, Siham; Nur, Erfan; Schlingemann, Reinier O; Biemond, Bart J.
Afiliación
  • Brandsen RP; Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Diederen RMH; Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Bakhlakh S; Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Nur E; Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Schlingemann RO; Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Biemond BJ; Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
Blood Adv ; 7(13): 3080-3086, 2023 07 11.
Article en En | MEDLINE | ID: mdl-36897257
Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD). Proliferative SCR (PSCR) can lead to severe visual impairment due to vitreous hemorrhage or retinal detachment. Knowledge of risk factors for progression and complications of SCR is limited. The aim of this study is to describe the natural history of SCR and to identify risk factors for progressive SCR and development of PSCR. We retrospectively analyzed disease progression in 129 patients with SCD with a median follow-up period of 11 years (interquartile range, 8.5-12). Patients were divided in 2 groups. The genotypes hemoglobin SS (HbSS), HbSß0-thalassemia, and HbSß+-thalassemia were grouped together (n = 83; 64.3%), whereas patients with HbSC (n = 46; 35.7%) were grouped separately. Progression of SCR was observed in 28.7% (37 of 129) of patients. Older age (adjusted odds ratio [aOR], 1.073; 95% confidence interval [CI], 1.024-1.125; P = .003), HbSC genotype (aOR, 25.472; 95% CI, 3.788-171.285; P ≤ 0.001), and lower HbF (aOR, 0.786; 95% CI, 0.623-0.993; P = .043) were associated with PSCR at end of follow-up. Lack of any SCR at end of follow-up was associated with female sex (aOR, 2.555; 95% CI, 1.101-5.931; P = .029), HbSS/HbSß0/HbSß+ genotype (aOR, 3.733; 95% CI, 1.131-12.321; P = .031), and higher HbF levels (aOR, 1.119; 95% CI, 1.007-1.243; P = .037). Differentiated strategies for screening and follow-up of SCR could be considered for patients at low or high risk.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de la Retina / Talasemia / Anemia de Células Falciformes Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de la Retina / Talasemia / Anemia de Células Falciformes Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos